Trial
NCT03811886
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Case Comprehensive Cancer Center
Collaborators
—
Condition
Pulmonary Metastatic Osteosarcoma (pOS)
Intervention
Natalizumab
Why stopped
No accruals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-15